Neglected Tropical Disease Treatments Markets, 2021

Dublin, Aug. 09, 2017 -- The "Global Markets for Neglected Tropical Disease Treatments" report has been added to Research and Markets' offering.

The Global Market for Neglected Tropical Diseases Should Reach $2.6 Billion by 2021 from $1.4 Billion in 2016 at a CAGR of 14.1%

The report focuses on newer drugs and innovations in chemical compounds, vaccines and biologicals recently launched or in development. Specifically excluded from the scope of research are vector or mosquito control approaches, strategies and products; drugs used for symptomatic treatment and not for the elimination of the virus from the host; and details on manufacturers and suppliers of nonbranded generics.

Products used for diagnosis as well as PCR techniques, kits and testing facilities are also excluded from the report.

The markets have been categorized based on regions defined by the WHO since it is the primary organization mapping disease prevalence, assisting with access to medicine and enabling partnerships. Regions include Africa, Americas, South-East Asia, Europe, Eastern Mediterranean and Western Pacific. These cover all the WHO participating countries which are described in detail in the subsequent section.

Report Includes

• An overview of the global markets for tropical disease treatments.
• Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
• A look at the total addressable market, an indication of the number of people affected, and the current shares of key marketed therapies.
• Representations of market shares by geography, company, and future outlook.
• Insight on some of the newer drug candidates, clinical trials, and their end points.
• Analyses of factors such as increases in resistance of vectors to common insecticides, increases in rapid diagnostic techniques, and no established treatment for newer conditions like Zika.
• Profiles of major players in the industry.

Key Topics Covered:

1: Introduction

• Study Goals and Objectives
• Reasons for Doing this Study
• Scope of Report
• Information Sources
• Methodology
• Geographic Breakdown

2: Summary and Highlights

3: Disease Overview

• Malaria
• Leishmaniasis
• Schistosomiasis
• Lymphatic Filariasis
• Chagas Disease
• African Trypanosomiasis
• Dengue
• Ebola
• Zika

4: Market Overview

• Total Addressable Market
• Malaria
• Leishmaniasis
• Schistosomiasis
• Lymphatic Filariasis
• Chagas Disease
• African Trypanosomiasis
• Dengue
• Ebola
• Zika
• Donations by Pharmaceutical Companies: Access to Medicines

5: Market Influencing Factors

• Market Drivers
• Market Deterrents
• Unmet Needs

6: Research and Development

• Malaria
• Leishmaniasis
• Schistosomiasis
• Lymphatic Filariasis
• Chagas Disease
• African Trypanosomiasis
• Dengue
• Ebola
• Zika

7: Patent Review

• Malaria
• Leishmaniasis
• Schistosomiasis
• Lymphatic Filariasis
• Chagas Disease
• African Trypanosomiasis
• Dengue
• Ebola
• Zika

8: Company Profiles

• Anacor Pharmaceuticals (Now Pfizer)
• Bayer
• Butantan
• (DNDI) Drugs For Neglected Diseases Initiative
• Eisai
• Gilead Sciences
• Glaxosmithkline
• Merck
• (MMV) Medicines For Malaria Venture
• Novartis
• The Path Malaria Vaccine Initiative
• Sabin Vaccine Institute
• Sanofi-Aventis/Sanofi Pasteur
• Takeda

9: Appendix: Abbreviations

For more information about this report visit https://www.researchandmarkets.com/research/kxtcnn/global_markets

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Infectious Diseases Drugs